CAT
Caterpillar Inc.
CAT has the edge over ENOV overall, supported by lower modeled downside and stronger modeled upside.
ENOV
Enovis Corporation
ENOV offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
ENOV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Healthy |
ENOV's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is under pressure.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
ENOV PE Valuation
ENOV has no meaningful PE right now: it lost money over the past year.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
ENOV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for ENOV, with profitability improving.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over ENOV on earnings quality, reporting a profit while its opponent remains loss making.
ENOV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.56 | — |
| Q3 2026 | -$9.25 | +$15.05 |
| Q2 2026 | -$19.30 | -$4.41 |
| Q1 2026 | -$19.92 | -$5.33 |
| Q4 2025 | -$20.75 | -$5.82 |
| Q3 2025 | -$24.30 | -$22.11 |
| Q2 2025 | -$14.89 | -$13.23 |
| Q1 2025 | -$14.59 | -$13.09 |
| Q4 2024 | -$14.93 | -$14.32 |
ENOV is still losing money, but far less than before: $9.25 per share over the past year, against $24.30 at its worst in late 2025.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT's revenue has grown year over year for five quarters in a row: $20.7B last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over ENOV on profitability, with a higher operating margin.
ENOV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $558.7M | +1.8% |
| Q2 2026 | $582.8M | +3.2% |
| Q1 2026 | $589.2M | +5.4% |
| Q4 2025 | $575.8M | +2.6% |
| Q3 2025 | $548.9M | +8.6% |
| Q2 2025 | $564.5M | +7.5% |
| Q1 2025 | $558.8M | +8.2% |
| Q4 2024 | $561M | +23% |
ENOV's revenue has grown year over year for 14 quarters in a row: $559M last quarter, up 1.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.6% | +102 points |
| Q2 2026 | 3% | +6 points |
| Q1 2026 | 1.1% | +9.5 points |
| Q4 2025 | -87% | +31 points |
| Q3 2025 | -102% | -96 points |
| Q2 2025 | -3% | +5.4 points |
| Q1 2025 | -8.4% | -1.6 points |
| Q4 2024 | -119% | -117 points |
ENOV's operating margin was 0.6% last quarter, up 102 points from the same quarter a year ago.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT generated $11.3B in free cash flow over the past year, up 26% from the year before.
ENOV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $35M | +20% |
| Q2 2026 | $31.1M | +816% |
| Q1 2026 | -$28.9M | +$16M |
| Q4 2025 | $32.3M | -8.1% |
| Q3 2025 | $29.1M | +1128% |
| Q2 2025 | $3.4M | +$35M |
| Q1 2025 | -$44.9M | +$28.2M |
| Q4 2024 | $35.1M | -13% |
ENOV has the edge over CAT on cash flow, with more consistent year-over-year improvement.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over ENOV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
ENOV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +892K shares |
| 1 year | +2.3% | +1.3M shares |
| 3 years | +7.2% | +3.9M shares |
| 5 years | +8.9% | +4.8M shares |
| Available history | +28% | +12.9M shares |
ENOV has 58M diluted shares, up 2.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has the edge over ENOV on leverage, with a lower net debt burden relative to earnings.
ENOV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.4x | Healthy |
| Q2 2026 | 4.1x | High |
| Q1 2026 | 4.7x | High |
| Q4 2025 | 5.7x | High |
| Q2 2025 | 7.9x | High |
| Q1 2025 | 6.6x | High |
| Q4 2024 | 8.4x | High |
| Q3 2024 | 8.7x | High |
ENOV's net debt is about 1.4 years of its operating earnings (EBITDA), down from 7.9 years a year ago.
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
ENOV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 58.1 | Neutral |
ENOV's weekly RSI is 61 (neutral) and its Stochastic is 58 (neutral).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
ENOV PE vs Industrials Sector
| Metric | ENOV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
ENOV has no meaningful PE right now: it lost money over the past year.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
ENOV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.2 | 31% above |
| 20 week MA | $23.0 | 20% above |
| 50 week MA | $23.7 | 17% above |
| 100 week MA | $29.2 | 5.2% below |
| 200 week MA | $41.1 | 33% below |
ENOV has the edge over CAT on trend strength, trading above more of its moving averages.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has the edge over ENOV on returns for 2026, with the stronger performance.
ENOV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $62.5 | $63.3 | +1.4% |
| 2021 | $63.3 | $77.7 | +23% |
| 2022 | $77.7 | $52.9 | -32% |
| 2023 | $52.9 | $56.0 | +6% |
| 2024 | $56.0 | $44.3 | -21% |
| 2025 | $44.3 | $27.4 | -38% |
| 2026 YTD | $27.4 | $27.6 | +0.9% |
ENOV has finished lower in three of the last six years. It's up 0.9% so far in 2026.